- Conditions
- Hereditary Periodic Fevers
- Interventions
- Canakinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Familial Mediterranean Fever
- Interventions
- colchicine sprinkle capsules
- Drug
- Lead sponsor
- Mutual Pharmaceutical Company, Inc.
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
- Interventions
- IL-1 Trap
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Familial Mediterranean Fever
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Up to 28 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Familial Mediterranean Fever
- Interventions
- Rilonacept, Placebo
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Madera, California • Bethesda, Maryland + 2 more
- Conditions
- Mevalonic Aciduria, Mevalonate Kinase Deficiency, Immune System Diseases, Periodic Fever Syndromes, Hereditary, Lipid Metabolism, Inborn Errors
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Periodic Fever, Aphthous Stomatitis, Pharyngitis, And Cervical Adenitis (Pfapa), Obstructive Sleep Apnea, Tonsillitis, Tonsil Disorder, Sleep Disordered Breathing
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Month to 99 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2038
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Indianapolis, Indiana • Bethesda, Maryland
- Conditions
- Familial Mediterranean Fever (FMF), Autoinflammation, Periodic Fever, Fever, Genetic Diseases, ROSAH, ALPK1
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 2 Months to 115 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1994
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
- Conditions
- Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases
- Interventions
- NC-503 (Anti-amyloidotic (AA) Agent)
- Drug
- Lead sponsor
- Bellus Health Inc. - a GSK company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts • Rochester, Minnesota + 1 more